vTv Therapeutics Inc. - (VTVT) News
vTv Therapeutics Inc. - (VTVT)
Today's Latest Price: $1.70 USD
Updated Oct 30 4:00pm
Add VTVT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter VTVT News Items
VTVT News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VTVT News From Around the Web
Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 DiabetesHIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 … |
An In-Depth Look At vTv TherapeuticsPity is the most agreeable feeling among those who have little pride and no prospects of great conquests."― Friedrich Nietzsche Today, we take an in depth look at a small developmental company that comes up from time to time in comments. The stock also sees large purchases of stock by... |
vTv Therapeutics Announces 2020 Second Quarter Financial Results and UpdateHIGH POINT, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended… |
vTv Therapeutics' TTP399 successful in mid-stage type 1 diabetes studyVTv Therapeutics (VTVT) is up 45% premarket on the heels of results from the Phase 2 Simplici-T1 study evaluating TTP399 as an adjunct to insulin therapy in adults with type 1 diabetes.The results demonstrate that TTP399, a once-a-day pill, reduces HbA1c and improves time in range, without increasing hypoglycemia or any signal for adverse... |
Is vTv Therapeutics Inc (VTVT) A Good Stock To Buy?At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […] |
3 Biotech Stocks Under $3 With 200%-Plus Upside PotentialThe healthcare sector took its place among the winners this year, rising 11%, compared to the S&P 500’s 9% drop. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular. However, before making hasty decisions, it should be noted that these stocks are notoriously risky, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Understanding the volatile nature of the industry itself, we used TipRanks database to pinpoint exciting biotech plays that won’t break the bank. We found three trading for less than ... |
vTv Therapeutics Announces 2020 First Quarter Financial Results and UpdateHIGH POINT, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March… |
Has vTv Therapeutics (VTVT) Outpaced Other Medical Stocks This Year?Is (VTVT) Outperforming Other Medical Stocks This Year? |
vTv Therapeutics Inc. (VTVT) Shares March Higher, Can It Continue?As of late, it has definitely been a great time to be an investor in vTv Therapeutics Inc. (VTVT). |
vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateHIGH POINT, N.C., Feb. 20, 2020 -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an. |
